CL2018000955A1 - Terapia de combinación para el tratamiento de neoplasias malignas - Google Patents
Terapia de combinación para el tratamiento de neoplasias malignasInfo
- Publication number
- CL2018000955A1 CL2018000955A1 CL2018000955A CL2018000955A CL2018000955A1 CL 2018000955 A1 CL2018000955 A1 CL 2018000955A1 CL 2018000955 A CL2018000955 A CL 2018000955A CL 2018000955 A CL2018000955 A CL 2018000955A CL 2018000955 A1 CL2018000955 A1 CL 2018000955A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- combination therapy
- malignant neoplasms
- combination
- idh2
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 abstract 2
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242218P | 2015-10-15 | 2015-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000955A1 true CL2018000955A1 (es) | 2018-09-14 |
Family
ID=57219007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000955A CL2018000955A1 (es) | 2015-10-15 | 2018-04-13 | Terapia de combinación para el tratamiento de neoplasias malignas |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10695352B2 (OSRAM) |
| EP (1) | EP3362070B1 (OSRAM) |
| JP (1) | JP6895956B2 (OSRAM) |
| KR (1) | KR102701893B1 (OSRAM) |
| CN (1) | CN108601787B (OSRAM) |
| AU (1) | AU2016340098B2 (OSRAM) |
| BR (1) | BR112018007447B1 (OSRAM) |
| CA (1) | CA3002029A1 (OSRAM) |
| CL (1) | CL2018000955A1 (OSRAM) |
| EA (1) | EA036129B1 (OSRAM) |
| ES (1) | ES2862730T3 (OSRAM) |
| IL (1) | IL258580B (OSRAM) |
| MX (1) | MX381582B (OSRAM) |
| SG (2) | SG10201912869WA (OSRAM) |
| WO (1) | WO2017066611A1 (OSRAM) |
| ZA (1) | ZA201802420B (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9986928B2 (en) | 2013-12-09 | 2018-06-05 | Medtronic, Inc. | Noninvasive cardiac therapy evaluation |
| CA2942072C (en) | 2014-03-14 | 2022-07-26 | Agios Pharmaceuticals, Inc. | Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
| MA71411A (fr) | 2015-10-15 | 2025-04-30 | Les Laboratoires Servier | Polythérapie pour le traitement de tumeurs malignes |
| DK3362066T3 (da) * | 2015-10-15 | 2021-11-22 | Les Laboratoires Servier Sas | Kombinationsterapi til behandling af maligniteter |
| SG10201912886XA (en) | 2015-10-15 | 2020-02-27 | Agios Pharmaceuticals Inc | Combination therapy for treating malignancies |
| US11219769B2 (en) | 2016-02-26 | 2022-01-11 | Medtronic, Inc. | Noninvasive methods and systems of determining the extent of tissue capture from cardiac pacing |
| CN109715143A (zh) | 2016-09-07 | 2019-05-03 | 细胞基因公司 | 片剂组合物 |
| ES2968376T3 (es) | 2017-05-05 | 2024-05-09 | Memorial Sloan Kettering Cancer Center | Métodos de tratamiento de neoplasia mieloproliferativa |
| JP7263669B2 (ja) * | 2017-06-12 | 2023-04-25 | レ ラボラトワール セルヴィエ | 併用療法を用いて脳腫瘍を処置する方法 |
| EP3651772A4 (en) * | 2017-07-09 | 2021-04-07 | BioSight Ltd. | ANTI-CANCER POLYTHERAPY |
| US11285312B2 (en) | 2018-03-29 | 2022-03-29 | Medtronic, Inc. | Left ventricular assist device adjustment and evaluation |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| WO2020092906A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof |
| WO2020092894A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol |
| WO2020092915A1 (en) | 2018-11-02 | 2020-05-07 | Celgene Corporation | Solid dispersions for treatment of cancer |
| US11697025B2 (en) | 2019-03-29 | 2023-07-11 | Medtronic, Inc. | Cardiac conduction system capture |
| CN113853217A (zh) * | 2019-04-29 | 2021-12-28 | 伊缪诺金公司 | 包含抗cd123免疫缀合物的治疗组合 |
| JP2022537384A (ja) | 2019-06-20 | 2022-08-25 | セルジーン コーポレーション | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
| US12201843B2 (en) | 2019-10-09 | 2025-01-21 | Medtronic, Inc. | Synchronizing external electrical activity |
| US11497431B2 (en) | 2019-10-09 | 2022-11-15 | Medtronic, Inc. | Systems and methods for configuring cardiac therapy |
| JP2023503842A (ja) | 2019-11-14 | 2023-02-01 | セルジーン コーポレーション | がんを処置するための小児用製剤 |
| CN111087408B (zh) * | 2020-01-03 | 2021-04-02 | 浙江大学 | 一种大环结构的idh2突变体抑制剂及其医药用途 |
| US20240229156A1 (en) * | 2021-03-12 | 2024-07-11 | Celgene Corporation | Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| EP0998271B3 (en) | 1997-06-06 | 2014-10-29 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| ATE340563T1 (de) | 2000-02-04 | 2006-10-15 | Depomed Inc | DOSIERUNGSFORM DES TYPS ßHÜLLE UND KERNß MIT EINER WIRKSTOFFFREISETZUNG, DIE SICH DER NULLTEN ORDNUNG ANNÄHERT |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US7038038B2 (en) | 2003-03-17 | 2006-05-02 | Pharmion Corporation | Synthesis of 5-azacytidine |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US7192781B2 (en) | 2004-04-13 | 2007-03-20 | Pharmion Corporation | Methods for stabilizing 5-azacytidine in plasma |
| US8846628B2 (en) * | 2008-05-15 | 2014-09-30 | Celgene Corporation | Oral formulations of cytidine analogs and methods of use thereof |
| US8530445B2 (en) * | 2008-06-09 | 2013-09-10 | Cyclacel Limited | Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine |
| EP2406389B1 (en) | 2009-03-13 | 2019-05-08 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| WO2011050211A2 (en) * | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| JP6231988B2 (ja) * | 2011-11-03 | 2017-11-15 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｎｅｄｄ８活性化酵素阻害剤および低メチル化剤の投与 |
| SG11201403878QA (en) | 2012-01-06 | 2014-08-28 | Agios Pharmaceuticals Inc | Therapeutically active compounds and their methods of use |
| NZ715738A (en) * | 2013-07-11 | 2021-06-25 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| TWI666208B (zh) | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| WO2015018060A1 (en) | 2013-08-09 | 2015-02-12 | Agios Pharmaceuticals, Inc. | Crystalline forms of therapeutically active compounds and use thereof |
| WO2016053850A1 (en) | 2014-09-29 | 2016-04-07 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| KR102628370B1 (ko) | 2015-02-04 | 2024-01-24 | 르 라보레또레 쎄르비에르 | 치료적 활성 화합물 및 이들의 사용 방법 |
| US9751863B2 (en) | 2015-08-05 | 2017-09-05 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| SG10201912886XA (en) | 2015-10-15 | 2020-02-27 | Agios Pharmaceuticals Inc | Combination therapy for treating malignancies |
| MX380596B (es) | 2015-12-04 | 2025-03-12 | Agios Pharmaceuticals Inc | Compuesto para usarse en el tratamiento de neoplasias malignas. |
| EP3419593B1 (en) | 2016-02-26 | 2022-03-23 | Celgene Corporation | Enasidenib for use in the treatment of relapsed or refractory acute myeloid leukaemia |
-
2016
- 2016-10-14 SG SG10201912869WA patent/SG10201912869WA/en unknown
- 2016-10-14 JP JP2018519352A patent/JP6895956B2/ja active Active
- 2016-10-14 EP EP16788866.8A patent/EP3362070B1/en active Active
- 2016-10-14 AU AU2016340098A patent/AU2016340098B2/en active Active
- 2016-10-14 US US15/768,462 patent/US10695352B2/en active Active
- 2016-10-14 SG SG11201802964QA patent/SG11201802964QA/en unknown
- 2016-10-14 MX MX2018004599A patent/MX381582B/es unknown
- 2016-10-14 KR KR1020187013741A patent/KR102701893B1/ko active Active
- 2016-10-14 WO PCT/US2016/057102 patent/WO2017066611A1/en not_active Ceased
- 2016-10-14 BR BR112018007447-0A patent/BR112018007447B1/pt active IP Right Grant
- 2016-10-14 EA EA201890961A patent/EA036129B1/ru not_active IP Right Cessation
- 2016-10-14 CA CA3002029A patent/CA3002029A1/en not_active Abandoned
- 2016-10-14 CN CN201680072973.3A patent/CN108601787B/zh active Active
- 2016-10-14 ES ES16788866T patent/ES2862730T3/es active Active
-
2018
- 2018-04-09 IL IL258580A patent/IL258580B/en active IP Right Grant
- 2018-04-12 ZA ZA2018/02420A patent/ZA201802420B/en unknown
- 2018-04-13 CL CL2018000955A patent/CL2018000955A1/es unknown
-
2020
- 2020-05-21 US US16/880,871 patent/US20210100805A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016340098B2 (en) | 2022-06-02 |
| SG11201802964QA (en) | 2018-05-30 |
| EP3362070B1 (en) | 2021-01-27 |
| KR20180064529A (ko) | 2018-06-14 |
| BR112018007447B1 (pt) | 2023-12-05 |
| MX381582B (es) | 2025-03-12 |
| US20210100805A1 (en) | 2021-04-08 |
| ZA201802420B (en) | 2020-08-26 |
| IL258580A (en) | 2018-05-31 |
| CA3002029A1 (en) | 2017-04-20 |
| EP3362070A1 (en) | 2018-08-22 |
| EA201890961A1 (ru) | 2018-11-30 |
| EA036129B1 (ru) | 2020-10-01 |
| CN108601787A (zh) | 2018-09-28 |
| US10695352B2 (en) | 2020-06-30 |
| NZ741433A (en) | 2024-07-26 |
| SG10201912869WA (en) | 2020-02-27 |
| JP2018535951A (ja) | 2018-12-06 |
| BR112018007447A2 (en) | 2018-10-23 |
| JP6895956B2 (ja) | 2021-06-30 |
| ES2862730T3 (es) | 2021-10-07 |
| MX2018004599A (es) | 2018-09-21 |
| WO2017066611A1 (en) | 2017-04-20 |
| AU2016340098A1 (en) | 2018-05-10 |
| KR102701893B1 (ko) | 2024-09-03 |
| CN108601787B (zh) | 2022-07-29 |
| US20180303840A1 (en) | 2018-10-25 |
| IL258580B (en) | 2021-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000955A1 (es) | Terapia de combinación para el tratamiento de neoplasias malignas | |
| CL2018000943A1 (es) | Terapia de combinación para tratar tumores malignos | |
| MX2018010261A (es) | Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
| MX2018006831A (es) | Metodos de tratamiento de neoplasias malignas. | |
| CL2018000927A1 (es) | Terapia combinada para el tratamiento de neoplasias malignas | |
| MX2018004587A (es) | Terapia de combinacion para tratar tumores malignos. | |
| UY36307A (es) | Terapias combinadas para el tratamiento del cáncer | |
| MX373045B (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| MA40437A (fr) | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux | |
| CL2015002807A1 (es) | Terapia de combinación | |
| MX2019013634A (es) | Composiciones y metodos para tratar cancer con mutaciones de braf atipicas. | |
| EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
| MX2024000253A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
| TW201611847A (en) | Compounds and compositions for treating EGFR expressing tumors | |
| MX2017016868A (es) | Composiciones y metods para inhibir actividad de arginasa. | |
| MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| MX2023000549A (es) | Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr. | |
| MX2016015161A (es) | Metodos de tratamiento de cancer de mama luminal a positivo para pr con inhibidor de pi3k, pictilisib. | |
| MX2020012782A (es) | Inhibidor de ccr5 para el uso en el tratamiento de cancer. | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
| PH12016501838A1 (en) | Compounds and their methods of use | |
| EA201890956A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| EA201691907A1 (ru) | Комбинированная терапия кураксинами |